Cempra Pharmaceuticals has named David Oldach, M.D., vice president of clinical research. He joins Cempra from Gilead Sciences, where between 2006 and 2011 he helped lead the early clinical development of the company's hepatitis C (HCV) pipeline.
The company has also expanded its clinical development team to manage its clinical programs for solithromycin and Takasta through advanced clinical development. The four appointments have significant anti-infective clinical development experience.
Jennifer Schranz, M.D., has been named vice president of clinical affairs, in advancing both programs into pivotal clinical trials.
Jane Anderson, Ph.D. joins as director of clinical research, directing multiple clinical operations.
Angela Paulovits joins as a clinical study manager following her tenure as a clinical research associate at ICON Clinical Research.
